Apollomics
ðŸ‡ðŸ‡°Hong Kong, China
- Country
- ðŸ‡ðŸ‡°Hong Kong, China
- Ownership
- -
- Employees
- 45
- Market Cap
- -
- Introduction
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China
Apollomics' Phase 3 trial of uproleselan in China for relapsed or refractory acute myeloid leukemia did not show favorable benefit. Median OS was 9.3 months in the uproleselan arm vs. 14.3 months in the chemotherapy-only arm. The trial was generally well tolerated, with similar safety profiles in both arms.
Apollomics phase 3 trial in China shows no benefit
Apollomics Inc. announced the results of its Phase 3 bridging trial of uproleselan in China, which did not meet its primary endpoint. The trial involved patients with relapsed or refractory acute myeloid leukemia (AML). Despite the setback, the company maintains a healthy current ratio of 2.25, suggesting adequate liquidity. Apollomics' lead program is now vebreltinib (APL-101), a c-Met inhibitor in a Phase 2 multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations.
© Copyright 2024. All Rights Reserved by MedPath